High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established. METHODS: We randomly assigned 4731 patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 100 to 190 mg per deciliter (2.6 to 4.9 mmol per liter), and had no known coronary heart disease to double-blind treatment with 80 mg of atorvastatin per day or placebo. The primary end point was a first nonfatal or fatal stroke. RESULTS: The mean LDL cholesterol level during the trial was 73 mg per deciliter (1.9 mmol per liter) among patients receiving atorvastatin and 129 mg per deciliter (3.3 mmol per liter) among patients receiving placebo. During a median follow-up of 4.9 years, 265 patients (11.2 percent) receiving atorvastatin and 311 patients (13.1 percent) receiving placebo had a fatal or nonfatal stroke (5-year absolute reduction in risk, 2.2 percent; adjusted hazard ratio, 0.84; 95 percent confidence interval, 0.71 to 0.99; P=0.03; unadjusted P=0.05). The atorvastatin group had 218 ischemic strokes and 55 hemorrhagic strokes, whereas the placebo group had 274 ischemic strokes and 33 hemorrhagic strokes. The five-year absolute reduction in the risk of major cardiovascular events was 3.5 percent (hazard ratio, 0.80; 95 percent confidence interval, 0.69 to 0.92; P=0.002). The overall mortality rate was similar, with 216 deaths in the atorvastatin group and 211 deaths in the placebo group (P=0.98), as were the rates of serious adverse events. Elevated liver enzyme values were more common in patients taking atorvastatin. CONCLUSIONS: In patients with recent stroke or TIA and without known coronary heart disease, 80 mg of atorvastatin per day reduced the overall incidence of strokes and of cardiovascular events, despite a small increase in the incidence of hemorrhagic stroke. (ClinicalTrials.gov number, NCT00147602 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the recently published Lipitor's Effect in Alzheimer's Dementia (LEADe) trial, which included 640 randomized patients with mild Alzheimer disease, intensive lipid lowering by the addition of atorvastatin (80 mg) to donepezil did not improve cognitive function over a 72-week period.464”
In the citing paper
“Data from RCTs and meta-analyses indicate that routine early use of high-intensity statin therapy is associated with rapid and sustained clinical benefits [438-442].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [438]
In the citing paper
“Following stroke or TIA, 34 patients are at risk not only of recurrent cerebrovascular events but also of other major CV events including MI.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [34]
In the citing paper
“Secondary prevention therapy with statins reduces the risk of recurrent stroke (by 12%), MI and vascular death.422,428”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [428]
In the citing paper
“Many reports have also indicated that there is no clear relationship between the TG level and cerebrovascular disease856, 862, 863).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [862]
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Cerebral Vascular Accidents in Patients over the Age of 60: II. Prognosis
Rankin, J. (1957) · Scottish Medical Journal · doi:10.1177/003693305700200504 · Cited by 2,506
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Stroke · doi:10.1161/01.str.0000199147.30016.74 · Cited by 1,873
Iso, H., Jacobs, D. R., Wentworth, D., Neaton, J. D., Cohen, J. D., & for the MRFIT Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201405 · Cited by 1,133
Amarenco, P., Labreuche, J., Lavallée, P., & Touboul, P.-J. (2004) · Stroke · doi:10.1161/01.str.0000147965.52712.fa · Cited by 746
Research works printed but not linked: 1
- Waters DD, 2005, Circulation, 112, 2020
Cited by
Items 901–1,000 of 1,005
The dimension of preventable stroke in a large representative patient cohort
Boehme, C., Toell, T., Mayer‐Suess, L., Domig, L., Pechlaner, R., Willeit, K., Tschiderer, L., Seekircher, L., Willeit, P., Griesmacher, A., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008573 · Cited by 27
Effects of statin therapy on outcomes of ischemic stroke: a real-world experience in Brazil
Vitturi, B. K., & Gagliardi, R. J. (2020) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20200027 · Cited by 30
The Role of Statins in Current Guidelines
Rached, F. H., & Santos, R. D. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00861-9 · Cited by 32
Statin therapy and the risk of intracerebral haemorrhage: a nationwide observational study
Åsberg, S., & Eriksson, M. (2015) · International Journal of Stroke · doi:10.1111/ijs.12539 · Cited by 27
Béjot, Y., Osseby, G., Grémeaux, V., Durier, J., Rouaud, O., Moreau, T., & Giroud, M. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.062 · Cited by 33
“Whereas diabetes [18,19] and hypercholesterolemia [20,21] have been shown to be independent risk factors for ischemic stroke, there remains uncertainty about the role of the latter in the etiology of intracerebral haemorrhage.”
BackgroundCurrent strategies for ischemic stroke prevention: role of multimodal combination therapies
Alberts, M. J., & Ovbiagele, B. I. (2007) · Journal of Neurology · doi:10.1007/s00415-007-0569-9 · Cited by 26
Suzuki, K., & Izumi, M. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1917-z · Cited by 34
Liu, L., Xu, A., Wong, K. S., Wang, D. Z., Wang, Y., & Expert consensus group of the evaluation & intervention of collateral circulation for ischemic stroke (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12226 · Cited by 28
Wiviott, S. D., & Cannon, C. P. (2006) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328010872d · Cited by 28
Abbas, A., Milles, J. J., & Ramachandran, S. (2012) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s7591 · Cited by 34
A global survey of physicians’ perceptions on cholesterol management: the From The Heart study
Erhardt, L., & Hobbs, R. F. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01420.x · Cited by 27
Hong, K., Ali, L. K., Selco, S. L., Fonarow, G. C., & Saver, J. L. (2011) · Stroke · doi:10.1161/strokeaha.110.600106 · Cited by 30
Low drug doses may improve outcomes in chronic disease
Dimmitt, S. B., & Stampfer, H. G. (2009) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02916.x · Cited by 30
Frøyshov, H. M., Bjørnerem, Å., Engstad, T. A., & Halvorsen, D. S. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-016-0575-9 · Cited by 31
Statins in the spectrum of neurologic disease
Orr, J. D. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-008-0003-5 · Cited by 28
Statins in stroke prevention: What an internist should know
Guerra, L. C., Moreno, M. D. C. F., Chozas, J. M. L., & Hernández, M. D. J. (2007) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2007.05.010 · Cited by 28
Thromboxane A2 promotes soluble CD40 ligand release from human platelets
Enomoto, Y., Adachi, S., Matsushima‐Nishiwaki, R., Doi, T., Niwa, M., Akamatsu, S., Tokuda, H., Ogura, S., Yoshimura, S., Iwama, T., et al. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.10.024 · Cited by 28
Barderas, M. G., Tuñón, J., Dardé, V. M., de la Cuesta, F., Jimenez-Nacher, J. J., Tarín, N., López‐Bescós, L., Egido, J., & Vivanco, F. (2009) · PROTEOMICS · doi:10.1002/pmic.200700583 · Cited by 28
Early Statin Therapy in Acute Coronary Syndromes
Waters, D. D., & Ku, I. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.062 · Cited by 27
Landscape of Statin as a Cornerstone in Atherosclerotic Cardiovascular Disease
Yang, C., Wu, Y., Qian, J., & Li, J. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2412373 · Cited by 30
Is Counterpulsation a Potential Therapy for Ischemic Stroke?
Han, J., & Wong, K. S. (2008) · Cerebrovascular Diseases · doi:10.1159/000139655 · Cited by 30
Kim, S. J., Park, Y. G., Kim, J. H., Han, Y., Cho, H. K., & Bang, O. Y. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.05.011 · Cited by 30
“The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial in patients with recent stroke or TIA clearly showed that intensive LDL-C lowering by statin treatment reduced the overall incidence of strokes and cardiovascular events [2].”
MethodMilionis, H. J., Barkas, F., Ntaios, G., Papavasileiou, V., Vemmos, K. N., Michel, P., & Elisaf, M. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.06.023 · Cited by 27
Herder, M., Arntzen, K. A., Johnsen, S. H., Eggen, A. E., & Mathiesen, E. B. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300767 · Cited by 33
Zhong, P., Wu, D., Ye, X., Wu, Y., Li, T., Tong, S., & Liu, X. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s135785 · Cited by 29
Ma, W., Pan, Q., Pan, D., Xu, T., Zhu, H., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.713007 · Cited by 31
LDL-C levels, lipid-lowering treatment and recurrent stroke in minor ischaemic stroke or TIA
Pan, Y., Wangqin, R., Li, H., Jin, A., Li, J., Lin, J., Meng, X., Xian, Y., Laskowitz, D. T., & Wang, Y. (2022) · Stroke and Vascular Neurology · doi:10.1136/svn-2021-001317 · Cited by 26
Lavallée, P. C., Charles, H., Albers, G. W., Caplan, L. R., Donnan, G. A., Ferro, J. M., Hennerici, M. G., Labreuche, J., Molina, C. A., Rothwell, P. M., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00067-4 · Cited by 26
Katsiki, N., Filippatos, T. D., Vlachopoulos, C. V., Panagiotakos, D. B., Milionis, H. J., Tselepis, A. D., Garoufi, A., Rallidis, L. S., Richter, D. J., Nomikos, T., et al. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.01.004 · Cited by 29
Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins
Chan, D. K. Y., O’Rourke, F., Shen, Q. X., Mak, J. C. S., & Hung, W. T. (2010) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2010.01450.x · Cited by 28
Lawlor, M., Perry, R. J., Hunt, B. J., & Plant, G. T. (2015) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2014.12.003 · Cited by 28
Utility of Framingham Coronary Heart Disease Risk Score for Predicting Cardiac Risk After Stroke
Towfighi, A., Markovic, D., & Ovbiagele, B. (2012) · Stroke · doi:10.1161/strokeaha.112.668319 · Cited by 27
The role of statins in neurosurgery
Tapia-Pérez, J. H., Sánchez-Aguilar, M., & Schneider, T. L. (2010) · Neurosurgical Review · doi:10.1007/s10143-010-0259-4 · Cited by 26
Treatment of Risk Factors to Prevent Stroke
Aoki, J., & Uchino, K. (2011) · Neurotherapeutics · doi:10.1007/s13311-011-0054-0 · Cited by 31
“In patients with a history of non-cardioembolic stroke or TIA without known CHD, the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial showed that atorvastatin (80 mg) compared with a placebo lowers overall stroke recurrence by 16%, regardless of the ischemic stroke subtype at entry [42, 4…”
BackgroundPredictors for cognitive decline in patients with confluent white matter hyperintensities
Mok, V., Xiong, Y., Wong, K., Wong, A., Schmidt, R., Chu, C. W., Hu, X., Leung, E. Y. L., Chen, S., Chen, Y., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.10.004 · Cited by 26
Periprocedural management of acute ischemic stroke intervention
Tarlov, N. E., Nien, Y. L., Zaidat, O. O., & Nguyen, T. N. (2012) · Neurology · doi:10.1212/wnl.0b013e31826958d3 · Cited by 26
Protocol for analyses of adverse event data from randomized controlled trials of statin therapy
Reith, C., Blackwell, L., Emberson, J., Mihaylova, B., Armitage, J., Fulcher, J., Keech, A., Simes, J., Baigent, C., & Collins, R. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.01.016 · Cited by 26
Rincón, F., & Sacco, R. L. (2008) · The Journal of Cardiovascular Nursing · doi:10.1097/01.jcn.0000305059.81000.d3 · Cited by 32
Cerebral Amyloid Angiopathy in Stroke Medicine
Block, F., & Dafotakis, M. (2017) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2017.0037 · Cited by 28
Aznaouridis, K. A., Masoura, C., Vlachopoulos, C. V., & Tousoulis, D. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190620104539 · Cited by 27
Deng, Q.-W., Liu, Y., Zhang, Y., Chen, X., Jiang, T., Hou, J., Shi, H., Lü, M., Zhou, F., Wang, W., et al. (2019) · Aging · doi:10.18632/aging.101859 · Cited by 30
Fang, X., Tao, D., Shen, J.-S., Wang, Y., Xiang, D., & Ji, X. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.07.013 · Cited by 27
Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke
Fletcher, G. F., Bufalino, V. J., Costa, F., Goldstein, L. B., Jones, D., Smaha, L. A., Smith, S. C., & Stone, N. J. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.02.001 · Cited by 29
van Kuilenburg, J. T., Lappegård, K. T., Sexton, J., Plesiewicz, I., Lap, P., Bouwels, L., Sprong, T., Mollnes, T. E., Verheugt, F. W. A., van Heerde, W. L., et al. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.05.003 · Cited by 27
Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis
Neuhaus, O., & Hartung, H. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.5.547 · Cited by 29
The Rationale for Using HMG-CoA Reductase Inhibitors (‘Statins’) in Peripheral Arterial Disease
Erez, G., & Leitersdorf, E. (2006) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2006.11.020 · Cited by 30
Murphy, C., Bennett, K., Fahey, T., Shelley, E., Graham, I., & Kenny, R. A. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008017 · Cited by 25
Nelson, L. D., Wilson, L., Albrecht, J. S., Arciniegas, D. B., Barthélemy, E. J., Fontaine, S. N., Gardner, R. C., Juengst, S. B., Pappadis, M. R., Ponsford, J. L., et al. (2025) · Journal of Neurotrauma · doi:10.1089/neu.2024.0569 · Cited by 40
Schwartz, G. G., CHAITMAN, B. R., Goldberger, J. J., & Messig, M. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.02.002 · Cited by 25
Statin Treatment in Patients with Acute Ischemic Stroke
Al‐Khaled, M., Matthis, C., & Eggers, J. (2014) · International Journal of Stroke · doi:10.1111/ijs.12256 · Cited by 25
Standard of practice: endovascular treatment of intracranial atherosclerosis: Table 1
Hussain, M. S., Fraser, J. F., Abruzzo, T. A., Blackham, K. A., Bulsara, K. R., Derdeyn, C. P., Gandhi, C. D., Hirsch, J. A., Hsu, D. P., Jayaraman, M. V., et al. (2012) · Journal of NeuroInterventional Surgery · doi:10.1136/neurintsurg-2012-010405 · Cited by 25
The TARDIS Trial Investigators (2015) · International Journal of Stroke · doi:10.1111/ijs.12538 · Cited by 27
Self-citationYi, X., Han, Z., Wang, C., Zhou, Q., & Lin, J. (2016) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2016.09.030 · Cited by 25
Lv, G., Wang, G., Xia, Z., Wang, H.-X., Liu, N., Wei, W., Huang, Y., & Zhang, W. (2019) · Military Medical Research · doi:10.1186/s40779-019-0191-z · Cited by 27
Pérez‐Calahorra, S., Laclaustra, M., Marco-Benedí, V., Pintó, X., Sánchez-Hernández, R. M., Plana, N., Ortega, E., Fuentes, F. J., & Civeira, F. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1153-x · Cited by 28
Banach, M., Shekoohi, N., Mikhailidis, D. P., Lip, G. Y. H., Hernández, A. V., & Mazidi, M. (2022) · Archives of Medical Science · doi:10.5114/aoms/145970 · Cited by 36
Management of patients with statin intolerance
Martirossian, A. N., & Goldberg, A. C. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101714 · Cited by 28
Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review
Chang, Y., Eom, S., Kim, M.-J., & Song, T. (2023) · Medicina · doi:10.3390/medicina59040776 · Cited by 31
“The benefit of statins was not proven in the SPARCL trial because patients with atrial fibrillation and other causes of cardioembolism were excluded [87].”
BackgroundInfluentialThe Acute (Cerebro)Vascular Effects of Statins
Prinz, V., & Endres, M. (2009) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181a85d0e · Cited by 29
ROCKs as immunomodulators of stroke
Wang, Q. M., & Liao, J. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.715149 · Cited by 27
Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome
Yakubov, S. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903223895 · Cited by 25
Statins, haemostatic factors and thrombotic risk
Bianconi, V., Sahebkar, A., Banach, M., & Pirro, M. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000397 · Cited by 25
Konishi, T., Funayama, N., Yamamoto, T., Hotta, D., Nomura, R., Nakagaki, Y., Murahashi, T., Kamiyama, K., Yoshimoto, T., Aoki, T., et al. (2018) · Heart and Vessels · doi:10.1007/s00380-018-1193-6 · Cited by 25
Secondary Stroke Prevention: From Guidelines to Clinical Practice
Graham, G. D. (2008) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)31482-6 · Cited by 25
Pepine, C. J. (2010) · Annals of Medicine · doi:10.3109/07853890903260898 · Cited by 25
Early Statin Use is Associated with Increased Risk of Infection After Stroke
Becker, K. J., Tanzi, P., Kalil, A., Shibata, D. K., & Cain, K. C. (2011) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2011.06.008 · Cited by 25
Current Concepts in Vascular Cognitive Impairment and Pharmacotherapeutic Implications
Rojas‐Fernandez, C. H., & Moorhouse, P. A. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l703 · Cited by 27
Athyros, V. G., Τζιόμαλος, Κ., Karagiannis, A. I., Wierzbicki, A. S., & Mikhailidis, D. P. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283393c1a · Cited by 24
Wang, Y., Li, Z., Xian, Y., Zhao, X. L., Li, H., Shen, H., Wang, C., Liu, L., Wang, C., Pan, Y. L., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.03.008 · Cited by 24
Associations and implications of cerebral microbleeds
Kleinig, T. J. (2013) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2012.12.002 · Cited by 24
Intensive Lipid-Lowering Therapy Ameliorates Asymptomatic Intracranial Atherosclerosis
Miao, H., Yang, Y., Wang, H., Huo, L.-Y., Wang, M., Zhou, Y., Yang, H., Ren, M., Ren, C., Ji, X., et al. (2018) · Aging and Disease · doi:10.14336/ad.2018.0526 · Cited by 26
Effect of coexisting vascular disease on long-term risk of recurrent events after TIA or stroke
Boulanger, M., Li, L., Lyons, S., Lovett, N. G., Kubiak, M. M., Silver, L. E., Touzé, E., Rothwell, P. M., Study, O. B. O. T. O. V., Study, O. B. O. T. O. V., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007935 · Cited by 26
Cheng, Y., Qiao, L., Jiang, Z., Dong, X., Feng, H., Gui, Q., Lu, Y., & Liang, Y. (2020) · PubMed · Cited by 33
Elevated lipoprotein(a) and the risk of stroke in children, young adults, and the elderly
Tsimikas, S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab251 · Cited by 25
Zebrafish as a Model for In-Depth Mechanistic Study for Stroke
Chen, W., Xie, L., Yu, F., Li, Y., Chen, C., Xie, W., Huang, T., Zhang, Y., Zhang, S., & Li, P. (2021) · Translational Stroke Research · doi:10.1007/s12975-021-00907-3 · Cited by 23
Use of Lipid-Lowering Drugs After Intracerebral Hemorrhage
Shoamanesh, A., & Selim, M. H. (2022) · Stroke · doi:10.1161/strokeaha.122.036889 · Cited by 28
Santalucia, P., Baviera, M., Cortesi, L., Tettamanti, M., Marzona, I., Nobili, A., Riva, E., Fortino, I., Bortolotti, A., Merlino, L. G., et al. (2015) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2015.05.008 · Cited by 27
Zekry, D., & Gold, G. (2010) · Drugs & Aging · doi:10.2165/11538250-000000000-00000 · Cited by 26
Marsh, E. B., Gottesman, R. F., Hillis, A. E., Urrutia, V., & Llinas, R. H. (2013) · Medicine · doi:10.1097/md.0000000000000006 · Cited by 24
Lapchak, P. A., & Han, M. (2010) · Brain Research · doi:10.1016/j.brainres.2010.05.035 · Cited by 25
Castro, S. D., Papetti, F., Angelantonio, E. D., Razmovska, B., Truscelli, G., Tuderti, U., Puca, E., Correnti, A., Fiorelli, M., Prencipe, M., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.066 · Cited by 24
Edwards, J. D., Kapral, M. K., Fang, J., & Swartz, R. H. (2017) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2016.09.038 · Cited by 27
A Diagnostic Approach to Stroke in Young Adults
Stack, C. A., & Cole, J. W. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0587-6 · Cited by 26
Suzuki, M., Furuya, K., Ozawa, M. Y., Miura, K., Ozawa, T., Matsuzono, K., Mashiko, T., Koide, R., Fujimoto, S., & Tanaka, R. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.58339 · Cited by 25
Intracranial Hemorrhage in the TST Trial
Amarenco, P., Kim, J. S., Labreuche, J., Charles, H., Giroud, M., Lavallée, P. C., Lee, B., Mahagne, M., Meseguer, E., Nighoghossian, N., et al. (2021) · Stroke · doi:10.1161/strokeaha.121.035846 · Cited by 24
Statins May Increase Intracerebral Hemorrhage Volume
Ricard, G., Lapointe‐Garant, M., Carrier, N., Leblanc, N., & Boulanger, J.-M. (2010) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100051453 · Cited by 24
Secondary Stroke Prevention Strategies for the Oldest Patients: Possibilities and Challenges
Bushnell, C., & Colon-Emeric, C. S. (2009) · Drugs & Aging · doi:10.2165/00002512-200926030-00003 · Cited by 33
Épidémiologie des accidents vasculaires cérébraux
Béjot, Y., Caillier, M., Rouaud, O., Bénatru, I., Maugras, C., Osseby, G., & Giroud, M. (2007) · La Presse Médicale · doi:10.1016/j.lpm.2006.11.006 · Cited by 40
Lapchak, P. A., & Han, M. (2009) · Brain Research · doi:10.1016/j.brainres.2009.09.064 · Cited by 23
“…the effects of atorvastatin (80 mg per day) in patients with a history of recent stroke or transient ischemic attack, showed that the drug reduced the overall incidence of strokes and cardiovascular events, but caused a small increase in the incidence of hemorrhagic stroke (Amarenco et al., 2006).”
BackgroundPalacio-Portilla, E. J., Roquer, J., Amaro, S., Arenillas, J. F., Martín, Ó. A., Castellanos, M., Freijo, M. D. M., Fuentes, B., Pastor, Á. G., Gomis, M., et al. (2020) · Neurología · doi:10.1016/j.nrl.2020.07.027 · Cited by 29
Qi, M., Cheng, Y., Liu, K., Cai, J., Liu, T., Wu, X., Tang, H., Huang, H., Chen, Q., & Zhou, X. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s449606 · Cited by 24
Alternate-day Dosing with Statins
Marcus, G. M., Baumgarten, A. J., Fritz, W. L., & Nolan, P. E. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.08.007 · Cited by 25
DEEDWANIA, P. C., Pedersen, T. R., DeMicco, D. A., Breazna, A., Betteridge, D. J., Hitman, G. A., Durrington, P. N., & Neil, A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.201 · Cited by 24
Severely frail elderly patients do not need lipid-lowering drugs
Mallery, L. H., Moorhouse, P. A., McLean-Veysey, P. R., Allen, M., & Fleming, I. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84a.15114 · Cited by 28
Hosomi, N., Kitagawa, K., Nagai, Y., Nakagawa, Y., Aoki, S., Nezu, T., Kagimura, T., Maruyama, H., Origasa, H., Minematsu, K., et al. (2018) · Stroke · doi:10.1161/strokeaha.117.018870 · Cited by 24
Ma, Y.-B., Chan, P., Zhang, Y., Tomlinson, B., & Liu, Z. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1594776 · Cited by 23
“In the SPARCL study, there was a small increase in the incidence of hemorrhagic stroke with atorvastatin 80 mg daily (55/2365) compared to placebo (33/2366) in subjects with prior stroke or TIA [68], whereas ischemic strokes were reduced (218 vs. 274).”
BackgroundLin, M., Lin, Y., Chang, S., Wang, P., Wu, V. C., Lin, W., & Chung, C. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.07.009 · Cited by 23
Woo, M.-H., Lee, K. O., Chung, D., Choi, J.-W., Kim, S.-H., & Oh, S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.504219 · Cited by 24
“The Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial in patients with recent stroke or transient ischemic attack clearly showed that intensive lowering of LDL-C using statin treatment reduced the overall incidence of strokes and cardiovascular events (9).”
MethodChen, P.-S., Lee, M., Tang, S., Huang, P., Yeh, H., Hou, C. J., Hsieh, C., Lee, J., Jeng, J., & Li, Y. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.03.001 · Cited by 24
Sorato, M. M., Davari, M., Kebriaeezadeh, A., Sarrafzadegan, N., & Shibru, T. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-056627 · Cited by 27
Metadata
- Authors
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
- Affiliations
- Université Paris Diderot (FR)
- Corresponding author
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-08-10
- Volume
- 355
- Issue
- 6
- Pages
- 549-559
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1546258268
- Cited by
- 2,887
- References
- 21
- Citations by year
- 2026: 86 · 2025: 96 · 2024: 119 · 2023: 112 · 2022: 135 · 2021: 134 · 2020: 139 · 2019: 140 · 2018: 129 · 2017: 132 · 2016: 139 · 2015: 125 · 2014: 142 · 2013: 160 · 2012: 149
- FWCI
- 200.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Eisai
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cerebrovascular and Carotid Artery Diseases
- Keywords
- atorvastatin, high-intensity statin therapy, stroke, transient ischemic attack, secondary stroke prevention, LDL cholesterol lowering, hemorrhagic stroke, ischemic stroke, cardiovascular events, elevated liver enzymes, lipid-lowering therapy, mortality, serious adverse events
- MeSH terms
- Atorvastatin, Adult, Cardiovascular Diseases, Cerebral Hemorrhage, Cerebral Infarction, Ischemic Attack, Transient, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Pyrroles, Risk, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.